Hospital Discharge of Patients with COPD: Reducing the Risk for Future Exacerbations and Readmission Newsletter

Release Date: April 29, 2015
Expiration Date: April 29, 2016

Faculty Authors

Patrick J. Dunne, MEd, RRT, FAARC
Clinical Application Specialist
HealthCare Productions, Inc.
Fullerton, California

Stanley B. Fiel, MD, FACP, FCCP
Professor of Medicine
Mount Sinai School of Medicine
New York, New York
The deNeufville Professor
Chairman, Department of Medicine
Morristown Medical Center
Morristown, New Jersey

Program Overview

Chronic obstructive pulmonary disease (COPD) is a condition that poses a significant health and economic burden due to its high prevalence, chronicity, comorbidities, complexities, and progressive nature. When patients with the disease present to the hospital for an acute exacerbation, clinicians are afforded an important opportunity to improve the care of these individuals. Provision of appropriate treatment requires that objective measures be employed to confirm diagnosis, and assess both disease severity and the risk for future exacerbations. In addition, close attention should be paid to individual patient characteristics, including comorbidities and other factors that may influence patient ability to adhere to both pharmacologic and non‐pharmacologic therapeutic recommendations. Through the collaborative efforts of a multidisciplinary team of clinicians including the participation of a respiratory therapist, these goals can be attained and patients can be provided with education and training to ensure that they are adequately equipped to achieve optimal control of their disease.

Target Audience

This activity has been designed for respiratory therapists involved in the management of patients with COPD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify guideline‐recommended objective measures for assessing current disease severity and risk for worsening disease and future exacerbations
  • Provide appropriately individualized therapeutic recommendations, education, and training for patients following hospitalization for an acute COPD exacerbation
  • Identify nonpharmacologic strategies for long‐term management of COPD and the associated benefits to health outcomes
  • Describe comorbidities that impact risk for worsening disease and future exacerbations in patients with COPD

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period April 29, 2015 through April 29, 2016, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
  • Complete the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.

Media

Internet

American Association for Respiratory Care (AARC) Continuing Education

This program has been approved for a maximum of 1.0 contact hour Continuing Respiratory Care (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd., Suite 100, Irving, TX 75063. Course#144354000.

Accreditation Council for Continuing Medical Education Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest (COI)

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Patrick, J. Dunne, MEd, RRT, FAARC
Consultant: Monaghan Medical Corporation
Speaker: MatureHealth

Stanley B. Fiel, MD, FACP, FCCP
Consultant: Novartis, Sunovion
Data Management Safety Board: Cystic Fibrosis Foundation
Research: Cystic Fibrosis Foundation, Gilead, Novartis, PTC Therapeutics, Vertex
Speaker: Gilead, Novartis, Pfizer

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7
Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest

pre

integrity
 Sponsored by Integrity Continuing Education, Inc.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.